Sign Up
OverviewAPI
The global biosimilar interleukins market is set to reach $20.79 billion by 2028, driven by the increasing prevalence of autoimmune diseases and an aging population. The key regions include North America, the Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa. The report emphasizes the significance of interleukins like IL-17, IL-23, IL-1, IL-5, and IL-6, and provides a strategic outlook for the industry.

Ask a question